{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:29:44Z","timestamp":1789730984541,"version":"4.0.1"},"reference-count":158,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.biopha.2026.119645","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:14:44Z","timestamp":1781223284000},"page":"119645","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Transferrin-functionalized liposomes for targeted breast cancer therapy: Mechanistic insights, conjugation strategies, and translational evidence"],"prefix":"10.1016","volume":"201","author":[{"given":"Loganathan Chandramani Priya","family":"Dharshini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7792-9219","authenticated-orcid":false,"given":"Abul Kalam Azad","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119645_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2026.119645_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103835","article-title":"Current and future burden of breast cancer in Asia: a GLOBOCAN data analysis for 2022 and 2050","volume":"79","author":"Fu","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.biopha.2026.119645_bib3","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2026.119645_bib4","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s10549-012-1985-9","article-title":"Family history and risk of breast cancer: nurses\u2019 health study","volume":"133","author":"Colditz","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.biopha.2026.119645_bib5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1758834016644156","article-title":"Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications","volume":"8","author":"Barroso-Sousa","year":"2016","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.biopha.2026.119645_bib6","series-title":"StatPearls","article-title":"Breast ductal carcinoma in situ","author":"Tomlinson-Hansen","year":"2023"},{"key":"10.1016\/j.biopha.2026.119645_bib7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41379-020-00689-3","article-title":"Lobular carcinoma in situ: Diagnostic criteria and molecular correlates","volume":"34","author":"Sokolova","year":"2021","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.biopha.2026.119645_bib8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40659-017-0140-9","article-title":"Awareness and current knowledge of breast cancer","volume":"50","author":"Akram","year":"2017","journal-title":"Biol. Res."},{"key":"10.1016\/j.biopha.2026.119645_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.32074\/1591-951X-1-20","article-title":"Histological type and typing of breast carcinomas and the WHO classification changes over time","volume":"112","author":"Cserni","year":"2020","journal-title":"Pathologica"},{"key":"10.1016\/j.biopha.2026.119645_bib10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000292644","article-title":"The changing role of pathology in breast cancer diagnosis and treatment","volume":"78","author":"Leong","year":"2011","journal-title":"Pathobiol"},{"key":"10.1016\/j.biopha.2026.119645_bib11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.critrevonc.2018.09.004","article-title":"Radiotherapy in triple-negative breast cancer: Current situation and upcoming strategies","volume":"131","author":"He","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.biopha.2026.119645_bib12","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1056\/NEJM199810013391407","article-title":"Treatment of breast cancer","volume":"339","author":"Hortobagyi","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119645_bib13","first-page":"721","article-title":"Breast cancer: An overview of current therapeutic strategies, challenge, and perspectives","volume":"15","author":"Wang","year":"2023","journal-title":"Breast Cancer"},{"key":"10.1016\/j.biopha.2026.119645_bib14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/joim.12084","article-title":"Breast cancer as a systemic disease: a view of metastasis","volume":"274","author":"Redig","year":"2013","journal-title":"J. Int. Med."},{"key":"10.1016\/j.biopha.2026.119645_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058183","article-title":"Biomarkers of residual disease, disseminated tumor cells, and metastases in the MMTV-PyMT breast cancer model","volume":"8","author":"Franci","year":"2013","journal-title":"PLoS. One"},{"key":"10.1016\/j.biopha.2026.119645_bib16","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1016\/S0009-2509(03)00234-3","article-title":"Chemotherapeutic engineering: Application and further development of chemical engineering principles for chemotherapy of cancer and other diseases","volume":"58","author":"Feng","year":"2003","journal-title":"Chem. Eng. Sci."},{"key":"10.1016\/j.biopha.2026.119645_bib17","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ejps.2012.12.006","article-title":"A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics","volume":"48","author":"Steichen","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2026.119645_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108108","article-title":"Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response","volume":"236","author":"Yu","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2026.119645_bib19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.biomaterials.2016.04.027","article-title":"An overview of the effective combination therapies for the treatment of breast cancer","volume":"97","author":"Nunez","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2026.119645_bib20","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1415340","article-title":"Regional nodal irradiation in early-stage breast cancer","volume":"373","author":"Whelan","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119645_bib21","article-title":"Nanotechnology-based drug delivery for breast cancer treatment: Current applications and future directions","volume":"14","author":"Samad","year":"2025","journal-title":"Eur. J. Med. Chem. Rep."},{"key":"10.1016\/j.biopha.2026.119645_bib22","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jconrel.2022.05.034","article-title":"Applications of lipid-engineered nanoplatforms in the delivery of various cancer therapeutics to surmount breast cancer","volume":"348","author":"Gupta","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2026.119645_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09394","article-title":"Liposomes: structure, composition, types, and clinical applications","volume":"8","author":"Nsairat","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.biopha.2026.119645_bib24","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jconrel.2016.11.015","article-title":"To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?","volume":"244","author":"Danhier","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2026.119645_bib25","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1021\/acsnano.9b08142","article-title":"Meta-analysis of nanoparticle delivery to tumors using a physiologically based pharmacokinetic modeling and simulation approach","volume":"14","author":"Cheng","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.biopha.2026.119645_bib26","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1021\/acs.bioconjchem.6b00437","article-title":"Nanodrug delivery: Is the enhanced permeability and retention effect sufficient for curing cancer?","volume":"27","author":"Nakamura","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.biopha.2026.119645_bib27","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3390\/pharmaceutics16020248","article-title":"Different targeting ligands-mediated drug delivery systems for tumor therapy","volume":"16","author":"Yan","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119645_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0293700","article-title":"Transferrin receptor in primary and metastatic breast cancer: Evaluation of expression and experimental modulation to improve molecular targeting","volume":"18","author":"Fontana","year":"2023","journal-title":"PLoS. One"},{"key":"10.1016\/j.biopha.2026.119645_bib29","article-title":"Pathophysiological aspects of transferrin-A potential nano-based drug delivery signaling molecule in therapeutic target for varied diseases","volume":"15","author":"Li","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119645_bib30","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-2836(65)80093-6","article-title":"Diffusion of univalent ions across the lamellae of swollen phospholipids","volume":"13","author":"Bangham","year":"1965","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.biopha.2026.119645_bib31","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1016\/j.matpr.2020.11.952","article-title":"A historical perspective of liposomes- a bio nanomaterial","volume":"45","author":"Sharma","year":"2021","journal-title":"Mater. Today Proc."},{"key":"10.1016\/j.biopha.2026.119645_bib32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2174\/1872211310666161004155757","article-title":"Liposomal drug delivery system for cancer therapy: advancement and patents, Liposomal drug delivery system for cancer therapy: advancement and patents","volume":"10","author":"Jha","year":"2016","journal-title":"Recent. Pat. Drug. Deliv. Formul."},{"key":"10.1016\/j.biopha.2026.119645_bib33","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1021\/acs.molpharmaceut.3c00766","article-title":"Liposomal copermeation assay reveals unexpected membrane interactions of commonly prescribed drugs","volume":"21","author":"Odehnalova","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2026.119645_bib34","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1166\/jcsb.2012.1020","article-title":"Preparation, characterization and applications of liposomes: state of the art","volume":"1","author":"Laouini","year":"2012","journal-title":"J. Colloid Sci. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119645_bib35","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/0006-291X(79)92148-X","article-title":"Stability of liposomes invivo and invitro is promoted by their cholesterol content and the presence of blood cells","volume":"89","author":"Gregoriadis","year":"1979","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2026.119645_bib36","first-page":"401","article-title":"Functionalized liposomes for targeted breast cancer drug delivery","volume":"24","author":"Nel","year":"2023","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.biopha.2026.119645_bib37","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/jphp.13098","article-title":"An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumor sites","volume":"71","author":"Attia","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119645_bib38","doi-asserted-by":"crossref","first-page":"7276","DOI":"10.3390\/ijms21197276","article-title":"Curcumin loaded nanoliposomes localization by nanoscale characterization","volume":"21","author":"Arab-Tehrany","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119645_bib39","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0009-3084(67)90030-8","article-title":"G.D. Greville, Osmotic properties and water permeability of phospholipid liquid crystals","volume":"1","author":"Bangham","year":"1967","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.biopha.2026.119645_bib40","series-title":"Biomaterial Engineering","article-title":"Liposome-based drug delivery systems","author":"Xiang","year":"2018"},{"key":"10.1016\/j.biopha.2026.119645_bib41","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1039\/D4PM00176A","article-title":"Advances in liposomal nanotechnology: from concept to clinics","volume":"1","author":"Senjab","year":"2024","journal-title":"RSC Pharm."},{"key":"10.1016\/j.biopha.2026.119645_bib42","article-title":"Liposomes: recent progress on nanoparticles production and their usage in medicine","volume":"180","author":"Perus","year":"2026","journal-title":"Biomater. Adv."},{"key":"10.1016\/j.biopha.2026.119645_bib43","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3390\/ijms19010195","article-title":"Surface functionalization and targeting strategies of liposomes in solid tumor therapy: A review","volume":"19","author":"Riaz","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119645_bib44","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1039\/c2cs15344k","article-title":"Targeted polymeric therapeutic nanoparticles: design, development and clinical translation","volume":"41","author":"Kamaly","year":"2012","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.biopha.2026.119645_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121714","article-title":"A modified thin film method for large scale production of dimeric artesunate phospholipid liposomes and comparison with conventional approaches","volume":"619","author":"Wang","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119645_bib46","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.drudis.2021.05.010","article-title":"Stimulus-responsive liposomes for biomedical applications","volume":"26","author":"Antoniou","year":"2021","journal-title":"Drug. Discov. Today"},{"key":"10.1016\/j.biopha.2026.119645_bib47","article-title":"Stimuli-responsive nanoliposomes as prospective nanocarriers for targeted drug delivery","volume":"66","author":"Bilal","year":"2021","journal-title":"J. Drug. Deliv. Sci. Technol."},{"key":"10.1016\/j.biopha.2026.119645_bib48","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jconrel.2020.09.055","article-title":"Peptide-functionalized liposome as therapeutic and diagnostic tools for cancer treatment","volume":"239","author":"Sonju","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2026.119645_bib49","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3892\/mmr.2022.12769","article-title":"Optimal combination of cationic lipid and phospholipid in cationic liposomes for gene knockdown in breast cancer cells and mouse lung using siRNA lipoplexes","volume":"26","author":"Hattori","year":"2022","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.biopha.2026.119645_bib50","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.omtm.2020.07.015","article-title":"Barriers and strategies of cationic liposomes for cancer gene therapy","volume":"18","author":"Liu","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.biopha.2026.119645_bib51","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.3390\/molecules28031498","article-title":"A review of different types of liposomes and their advancements as a form of gene therapy treatment for breast cancer","volume":"28","author":"Tseu","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2026.119645_bib52","doi-asserted-by":"crossref","first-page":"46664","DOI":"10.1021\/acsomega.4c06714","article-title":"Brief composition of the efficacy of cationic and anionic liposomes as novel delivery systems","volume":"9","author":"Ochoa-Sanchez","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.biopha.2026.119645_bib53","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.biopha.2026.119645_bib54","article-title":"Sustainable technologies for liposome preparation","volume":"165","author":"Leitgeb","year":"2020","journal-title":"J. Supercrit. Fluids"},{"key":"10.1016\/j.biopha.2026.119645_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114577","article-title":"Challenges in the development of long acting injectable multivesicular liposomes (DepoFoam\u00ae technology)","volume":"205","author":"Li","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.biopha.2026.119645_bib56","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.tibtech.2013.09.007","article-title":"Ligand-targeted liposome design: challenges and fundamental considerations","volume":"32","author":"Noble","year":"2014","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.biopha.2026.119645_bib57","first-page":"319","article-title":"Formation strategies, mechanism of intracellular delivery and potential clinical applications of pH-sensitive liposomes","volume":"8","author":"Liu","year":"2013","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2026.119645_bib58","first-page":"365","article-title":"Current developments in drug delivery with thermosensitive liposomes","volume":"14","author":"Hongshu","year":"2019","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2026.119645_bib59","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jconrel.2013.03.036","article-title":"Thermosensitive liposomes for localized delivery and triggered release of chemotherapy","volume":"169","author":"Ta","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2026.119645_bib60","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3109\/09687688.2010.507788","article-title":"Light-sensitive lipid-based nanoparticles for drug delivery: design principles and future considerations for biological applications","volume":"27","author":"Yavlovich","year":"2010","journal-title":"Mol. Membr. Biol."},{"key":"10.1016\/j.biopha.2026.119645_bib61","doi-asserted-by":"crossref","first-page":"12273","DOI":"10.1039\/C4NR04249B","article-title":"Enzyme-responsive nanomaterials for controlled drug delivery","volume":"6","author":"Hu","year":"2014","journal-title":"Nanoscale"},{"key":"10.1016\/j.biopha.2026.119645_bib62","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.nantod.2018.02.010","article-title":"Recent advances in functional nanomaterials for light-triggered cancer therapy","volume":"19","author":"Gai","year":"2018","journal-title":"NanoToday"},{"key":"10.1016\/j.biopha.2026.119645_bib63","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.2147\/IJN.S157375","article-title":"Efficient gene transfection to the brain with ultrasound irradiation in mice using stabilized bubble lipopolyplexes prepared by the surface charge regulation method","volume":"13","author":"Ogawa","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2026.119645_bib64","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.colsurfb.2017.07.085","article-title":"Immunoliposomes: A review on functionalization strategies and targets for drug delivery","volume":"159","author":"Eloy","year":"2017","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.biopha.2026.119645_bib65","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.3390\/pharmaceutics15041210","article-title":"Smuggling on the nanoscale-fusogenic liposomes enable efficient RNA-transfer with negligible immune response in vitro and in vivo","volume":"15","author":"Hoffmann","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119645_bib66","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3390\/pharmaceutics10040218","article-title":"Exosomes and exosome-inspired vesicles for targeted drug delivery","volume":"10","author":"Antimisiaris","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119645_bib67","article-title":"Advances in liposomal drug delivery to cancer: An overview","volume":"56","author":"Saraf","year":"2020","journal-title":"J. Drug. Deliv. Sci. Technol."},{"key":"10.1016\/j.biopha.2026.119645_bib68","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.semcancer.2019.09.025","article-title":"Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy","volume":"69","author":"Moosavian","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.biopha.2026.119645_bib69","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1200\/JCO.2004.08.157","article-title":"Randomized phase II trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer","volume":"22","author":"Keller","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119645_bib70","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/annonc\/mdh393","article-title":"Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer","volume":"15","author":"Chan","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2026.119645_bib71","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1186\/s12885-017-3377-3","volume":"17","author":"Burade","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2026.119645_bib72","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.7314\/APJCP.2013.14.4.2591","article-title":"Clinical comparison between paclitaxel liposome (Lipusu\u00ae) and paclitaxel treatment for treatment of patients with metastatic gastric cancer","volume":"14","author":"Xu","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.biopha.2026.119645_bib73","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1586\/14737140.2.2.143","article-title":"Caelyx\/Doxil for the treatment of metastatic ovarian and breast cancer","volume":"2","author":"Tejada-Berges","year":"2002","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.biopha.2026.119645_bib74","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.1997.15.10.3185","article-title":"Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial","volume":"15","author":"Ranson","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119645_bib75","first-page":"115a","article-title":"Doxil and intravenous cyclophosphamide as first line therapy for patients with metastatic breast cancer (MBC): interim results of an ongoing pilot trial [abstract]","volume":"18","author":"Silverman","year":"1999","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119645_bib76","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1200\/JCO.2001.19.6.1716","article-title":"Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer","volume":"19","author":"Rivera","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119645_bib77","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1200\/JCO.2001.19.12.3117","article-title":"Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer","volume":"19","author":"Sparano","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119645_bib78","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1517\/14656566.3.12.1739","article-title":"Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy","volume":"3","author":"Batist","year":"2002","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.biopha.2026.119645_bib79","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0960-9776(01)80005-9","article-title":"Liposomal doxorubicin (Myocet\u2122) and conventional anthracyclines: a comparison","volume":"10","author":"Marty","year":"2001","journal-title":"Breast"},{"key":"10.1016\/j.biopha.2026.119645_bib80","doi-asserted-by":"crossref","unstructured":"R.S. Gaspar, H.F. Florindo, L.C. Silva, M.A. Videira, M.L. Corvo, B.F. Martins, B. Silva-Lima, Regulatory aspects of oncologicals: Nanosystems main challenges, In: M. Alonso, M. Garcia-Fuentes (eds) Nano-Oncologicals. Adv. Drug Deliv. Sci. Technol. (2014) 425-452, \u3008https:\/\/doi.org\/10.1007\/978-3-319-08084-0_15\u3009.","DOI":"10.1007\/978-3-319-08084-0_15"},{"key":"10.1016\/j.biopha.2026.119645_bib81","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ijpharm.2017.05.016","article-title":"Paclitaxel: what has been done and the challenges remain ahead","volume":"526","author":"Bernabeu","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119645_bib82","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1039\/D1TB02823E","article-title":"Engineering Lipusu with lysophosphatidylcholine for improved tumor cellular uptake and anticancer efficacy","volume":"10","author":"Li","year":"2022","journal-title":"J. Mater. Chem. B."},{"key":"10.1016\/j.biopha.2026.119645_bib83","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae- The first FDA-approved nano-drug: Lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2026.119645_bib84","first-page":"1719","article-title":"A tale of the two PEGylated liposomal doxorubicins","volume":"8","author":"Chou","year":"2015","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.biopha.2026.119645_bib85","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z","article-title":"Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma","volume":"89","author":"lyass","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2026.119645_bib86","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1186\/s12885-023-11228-z","article-title":"Clinical trial protocol for PanDox: a phase I study of targeted chemotherapy delivery to non-resectable primary pancreatic tumors using thermosensitive liposomal doxorubicin (ThermoDox\u00ae) and focused ultrasound","volume":"23","author":"Spiers","year":"2023","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.biopha.2026.119645_bib87","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-040162","article-title":"Phase I feasibility study of magnetic resonance guided high intensity focused ultrasound-induced hyperthermia, lyso-thermosensitive liposomal doxorubicin and cyclophosphamide in de novo stage IV breast cancer patients: study protocol of the i-GO study","volume":"10","author":"de Maar","year":"2020","journal-title":"BMJ Open."},{"key":"10.1016\/j.biopha.2026.119645_bib88","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1423-0410.2002.tb05327.x","article-title":"Function and therapeutic development of apotransferrin","volume":"83","author":"Parkkinen","year":"2002","journal-title":"Vox Sang."},{"key":"10.1016\/j.biopha.2026.119645_bib89","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1046\/j.1440-1746.1999.01828.x","article-title":"Non-transferrin-bound iron and cellular toxicity","volume":"14","author":"Anderson","year":"1999","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2026.119645_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2021.214186","article-title":"Human transferrin: An inorganic biochemistry perspective","volume":"449","author":"Silva","year":"2021","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.biopha.2026.119645_bib91","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0898-8838(08)60176-2","article-title":"Structure and reactivity of transferrins","volume":"41","author":"Baker","year":"1994","journal-title":"Adv. Inorg. Chem."},{"key":"10.1016\/j.biopha.2026.119645_bib92","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.bbagen.2011.07.003","article-title":"The binding and transport of alternative metals by transferrin","volume":"1820","author":"Vincent","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2026.119645_bib93","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/215584a0","article-title":"Significance of the binding of iron by transferrin","volume":"215","author":"Fletcher","year":"1967","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119645_bib94","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/0300-9084(88)90184-8","article-title":"Structure and spatial conformation of the iron-binding sites of transferrins","volume":"70","author":"Legrand","year":"1988","journal-title":"Biochimie"},{"key":"10.1016\/j.biopha.2026.119645_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbapap.2022.140856","article-title":"Substitution of carbonate by non-physiological synergistic anion modulates the stability and iron release kinetics of serum transferrin","volume":"1871","author":"Kumar","year":"2023","journal-title":"Biochim. Biophys. Acta Proteins Proteom."},{"key":"10.1016\/j.biopha.2026.119645_bib96","first-page":"7919","article-title":"Two high-resolution crystal structures of the recombinant N-lobe of human transferrin reveal a structural change implicated in iron release, Biochem","volume":"37","author":"MacGillivray","year":"1998"},{"key":"10.1016\/j.biopha.2026.119645_bib97","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bbagen.2011.09.009","article-title":"The intracellular trafficking pathway of transferrin","volume":"1820","author":"Mayle","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2026.119645_bib98","doi-asserted-by":"crossref","first-page":"629","DOI":"10.4155\/tde.13.21","article-title":"Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells","volume":"4","author":"Dufes","year":"2013","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.biopha.2026.119645_bib99","first-page":"916","article-title":"Transferrin receptor 1 in cancer: a new sight for cancer therapy","volume":"8","author":"Shen","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119645_bib100","doi-asserted-by":"crossref","first-page":"12888","DOI":"10.1016\/S0021-9258(18)42979-1","article-title":"Biosynthesis of the human transferrin receptor in cultured cells","volume":"256","author":"Omary","year":"1981","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119645_bib101","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/j.1460-2075.1987.tb04758.x","article-title":"Identification of the intermolecular disulfide bonds of the human transferrin receptor and its lipid-attachment site","volume":"6","author":"Jing","year":"1987","journal-title":"EMBO J."},{"key":"10.1016\/j.biopha.2026.119645_bib102","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0092-8674(84)90004-7","article-title":"The human transferrin receptor gene: genomic organization, and the complete primary structure of the receptor deduced from a cDNA sequence","volume":"39","author":"McClelland","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2026.119645_bib103","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/MOH.0000000000000133","article-title":"Erythropoiesis and transferrin receptors","volume":"22","author":"Moura","year":"2015","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.biopha.2026.119645_bib104","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.bbagen.2011.07.013","article-title":"The thermodynamic and binding properties of the transferrins as studied by isothermal titration calorimetry","volume":"1820","author":"Bou-Abdallah","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2026.119645_bib105","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/S0021-9258(19)62337-9","article-title":"Stoichiometric and site characteristics of the binding of iron to human transferrin","volume":"253","author":"Aisen","year":"1978","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119645_bib106","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.bbagen.2011.07.016","article-title":"The transferrin receptor and the targeted delivery of therapeutic agents against cancer","volume":"1820","author":"Daniels","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2026.119645_bib107","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1042\/bj2190505","article-title":"The effect of the iron saturation of transferrin on its binding and uptake by rabbit reticulocytes","volume":"219","author":"Young","year":"1984","journal-title":"Biochem. J."},{"key":"10.1016\/j.biopha.2026.119645_bib108","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrd.2016.248","article-title":"Targeting iron metabolism in drug discovery and delivery","volume":"16","author":"Crielaard","year":"2017","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.biopha.2026.119645_bib109","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1073\/pnas.80.8.2258","article-title":"pH and the recycling of transferrin during receptor-mediated endocytosis","volume":"80","author":"Dautry-Varsat","year":"1983","journal-title":"Proc. Natl. Acad. U. S. A"},{"key":"10.1016\/j.biopha.2026.119645_bib110","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1021\/bi030142g","article-title":"Transferrin\u2019s mechanism of interaction with receptor 1","volume":"43","author":"Hemadi","year":"2004","journal-title":"Biochem"},{"key":"10.1016\/j.biopha.2026.119645_bib111","unstructured":"J.B. Harford, T.A. Rouault, H.A. Huebers, R.D. Klausner, Molecular mechanisms of iron metabolism, The Molecular Basis of Blood Diseases. Edited by Stamatoyannopoulos G, Nienhuis AW, Majerus PW, Varmus H. 1994."},{"key":"10.1016\/j.biopha.2026.119645_bib112","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1615\/CritRevOncog.2013007784","article-title":"Cellular iron metabolism in prognosis and therapy of breast cancer","volume":"18","author":"Torti","year":"2013","journal-title":"Crit. Rev. Oncol."},{"key":"10.1016\/j.biopha.2026.119645_bib113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2014.01.029","article-title":"Iron homeostasis in breast cancer","volume":"347","author":"Marques","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2026.119645_bib114","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0140-6736(80)90440-7","article-title":"Transferrin and transferrin receptors in carcinoma of the breast","volume":"2","author":"Faulk","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2026.119645_bib115","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00710908","article-title":"Transferrin receptor (TfR) expression in breast carcinoma and its possible relationship to prognosis- An immunohistochemical study","volume":"410","author":"Wrba","year":"1986","journal-title":"Virchows Arch. A Pathol. Anat. Histopathol."},{"key":"10.1016\/j.biopha.2026.119645_bib116","first-page":"759","article-title":"Manipulation of iron transporter genes results in the suppression of human and mouse mammary adenocarcinomas","volume":"30","author":"Jiang","year":"2010","journal-title":"Anticancer. Res."},{"key":"10.1016\/j.biopha.2026.119645_bib117","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1158\/0008-5472.CAN-13-1224","article-title":"IRP2 regulates breast tumor growth","volume":"74","author":"Wang","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119645_bib118","doi-asserted-by":"crossref","first-page":"35708","DOI":"10.1074\/jbc.M111.271585","article-title":"Src regulates Tyr(20) phosphorylation of transferrin receptor-1 and potentiates breast cancer cell survival","volume":"286","author":"Jian","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119645_bib119","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1038\/onc.2014.124","article-title":"SIRT3 regulates cellular iron metabolism and cancer growth by repressing iron regulatory protein 1","volume":"34","author":"Jeong","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2026.119645_bib120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0293700","article-title":"Transferrin receptor in primary and metastatic breast cancer: Evaluation of expression and experimental modulation to improve molecular targeting","volume":"18","author":"Fontana","year":"2023","journal-title":"PLoS. One"},{"key":"10.1016\/j.biopha.2026.119645_bib121","doi-asserted-by":"crossref","first-page":"13262","DOI":"10.3390\/ijms241713262","article-title":"Transferrin-targeted liposomes in glioblastoma therapy: A review","volume":"24","author":"Kawak","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119645_bib122","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1002\/jps.20098","article-title":"Current methods for attaching ligands to liposomes and nanoparticles","volume":"93","author":"Nobs","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2026.119645_bib123","article-title":"Liposome surface modification by phospholipid chemical reactions","volume":"237","author":"de Lima","year":"2021","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.biopha.2026.119645_bib124","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.biopha.2026.119645_bib125","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0003-2697(85)90442-7","article-title":"Measurement of protein using bicinchoninic acid","volume":"150","author":"Smith","year":"1985","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.biopha.2026.119645_bib126","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119645_bib127","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0003-9861(59)90090-6","article-title":"Tissue sulfhydryl groups","volume":"82","author":"Ellman","year":"1959","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.biopha.2026.119645_bib128","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.3109\/10717544.2014.999960","article-title":"Surface-modified epirubicin-HCl liposomes and its invitro assessment in breast cancer cell-line: MCF-7","volume":"23","author":"Gandhi","year":"2016","journal-title":"Drug. Deliv."},{"key":"10.1016\/j.biopha.2026.119645_bib129","article-title":"Transferrin conjugated stealth liposomes for sirolimus active targeting in breast cancer","volume":"66","author":"Nandi","year":"2021","journal-title":"J. Drug. Deliv. Sci. Technol."},{"key":"10.1016\/j.biopha.2026.119645_bib130","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s12672-024-01486-z","article-title":"Preparation of transferrin-modified IR820-loaded liposomes and its effect on photodynamic therapy of breast cancer","volume":"15","author":"Di","year":"2024","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.biopha.2026.119645_bib131","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1023\/A:1026422915326","article-title":"Niosomes and polymeric chitosan based vesicles bearing transferrin and glucose ligands for drug targeting","volume":"17","author":"Dufes","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2026.119645_bib132","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/jin2.56","article-title":"Transferrin-bearing liposomes entrapping plumbagin for targeted cancer therapy","volume":"4","author":"Sakpakdeejaroen","year":"2019","journal-title":"J. Interdiscip. Nanomed."},{"key":"10.1016\/j.biopha.2026.119645_bib133","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1158\/1078-0432.CCR-12-3451","article-title":"Tumor imaging and interferon-\u03b3-inducible protein-10 gene transfer using a highly efficient transferrin-conjugated liposome system in mice","volume":"19","author":"Zhou","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119645_bib134","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1016\/j.xphs.2019.11.013","article-title":"Transferrin-modified nanoliposome codelivery strategies for enhancing the cancer therapy","volume":"109","author":"Fu","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2026.119645_bib135","doi-asserted-by":"crossref","first-page":"11347","DOI":"10.3390\/ijms262311347","article-title":"Transferrin-functionalized liposomes enhance MAPT-ASO transport across a 3D blood-brain barrier microvascular network model","volume":"26","author":"Konig","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119645_bib136","article-title":"SDS-polyacrylamide gel electrophoresis of proteins","volume":"4","author":"Sambrook","year":"2006","journal-title":"CSH Protoc."},{"key":"10.1016\/j.biopha.2026.119645_bib137","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jconrel.2020.10.003","article-title":"Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation","volume":"329","author":"Gu","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2026.119645_bib138","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s13205-020-2144-3","article-title":"Recent strategies towards the surface modification of liposomes: an innovative approach for different clinical applications","volume":"10","author":"Khan","year":"2020","journal-title":"3 Biotech"},{"key":"10.1016\/j.biopha.2026.119645_bib139","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1021\/acsami.4c15045","article-title":"Transferrin protein corona-targeted codelivery of tirapazamine and IR820 facilitates efficient PDT-induced hypoxic chemotherapy on 4T1 breast cancer","volume":"17","author":"Jin","year":"2025","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.biopha.2026.119645_bib140","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ijpharm.2010.02.008","article-title":"Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7\u03b1-APTADD to breast cancer cells","volume":"390","author":"Zheng","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119645_bib141","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s40005-013-0091-2","article-title":"Repositioning of zoledronic acid for breast cancer using transferrin-conjugated liposome","volume":"43","author":"Choi","year":"2013","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.biopha.2026.119645_bib142","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/BF03401962","article-title":"Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv","volume":"7","author":"Xu","year":"2001","journal-title":"Mol. Med."},{"key":"10.1016\/j.biopha.2026.119645_bib143","first-page":"337","article-title":"Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes","volume":"1","author":"Xu","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2026.119645_bib144","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","article-title":"Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals","volume":"154-155","author":"Kozma","year":"2020","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.biopha.2026.119645_bib145","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijpharm.2007.11.005","article-title":"Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes","volume":"354","author":"Ishida","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119645_bib146","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.607692","article-title":"Antibodies targeting the transferrin receptor 1 (TfR1) as direct anti-cancer agents","volume":"12","author":"Candelaria","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119645_bib147","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijpharm.2004.05.025","article-title":"Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo","volume":"281","author":"Hatakeyama","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119645_bib148","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3390\/jcm11030837","article-title":"Expression of iron metabolism proteins in patients with chronic heart failure","volume":"11","author":"Kozlowska","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.biopha.2026.119645_bib149","doi-asserted-by":"crossref","first-page":"15549","DOI":"10.1073\/pnas.0707461104","article-title":"Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging","volume":"104","author":"Bartlett","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2026.119645_bib150","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/mt.2013.32","article-title":"Phase I study of a systematically delivered p53 nanoparticle in advanced solid tumors","volume":"21","author":"Senzer","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2026.119645_bib151","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1484982","article-title":"Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor","volume":"7","author":"Kim","year":"2018","journal-title":"Oncoimmunol"},{"key":"10.1016\/j.biopha.2026.119645_bib152","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/mt.2016.118","article-title":"A phase I study of a tumor-targeted systemic nanodelivery system, SGT-94, in genitourinary cancers","volume":"24","author":"Siefker-Radtke","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2026.119645_bib153","doi-asserted-by":"crossref","first-page":"C36","DOI":"10.1158\/1535-7163.TARG-09-C36","article-title":"MBP-426, a novel liposome-encapsulated oxaliplatin, in combination with 5-FU\/leucovorin (LV): Phase I results of a phase I\/II study in gastro-esophageal adenocarcinoma, with pharmacokinetics","volume":"8","author":"Senzer","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2026.119645_bib154","unstructured":"U.S. Food and Drug Administration. Liposome drug products: Chemistry, manufacturing, and controls; human pharmacokinetics and bioavailability; and labelling documentation. Published April 2018. Accessed June 1, 2026."},{"key":"10.1016\/j.biopha.2026.119645_bib155","unstructured":"U.S. Food and Drug Administration. Drug products, including biological products, that contain nanomaterials-guidance for industry. Published April 2022. Accessed June 1, 2026."},{"key":"10.1016\/j.biopha.2026.119645_bib156","unstructured":"European Directorate for the Quality of Medicines & HealthCare (EDQM). Call for Experts \u2013 NANO Working Party (Nanomedicines). Strasbourg, France; 2023. Available from: EDQM News Release on NANO Working Party."},{"key":"10.1016\/j.biopha.2026.119645_bib157","series-title":"Nanotechnology-based medicinal products for human use: EU Horizon Scanning Report. EMA\/20989\/2025\/Rev.1","first-page":"16","author":"European Medicines Agency (EMA)","year":"2025"},{"key":"10.1016\/j.biopha.2026.119645_bib158","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/molecules28010010","article-title":"Quality by design approach in liposomal formulations: Robust product development","volume":"28","author":"Alshaer","year":"2022","journal-title":"Molecules"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226006815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226006815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T06:37:04Z","timestamp":1784529424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226006815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":158,"alternative-id":["S0753332226006815"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119645","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transferrin-functionalized liposomes for targeted breast cancer therapy: Mechanistic insights, conjugation strategies, and translational evidence","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119645","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119645"}}